Iqvia launches new division to support emerging biotech market

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/JK1991)
(Image: Getty/JK1991)

Related tags: Iqvia Biotech, IQVIA, Biotechnology, Biopharmaceutical

To support the emerging biotech and biopharma industry, Iqvia today has announced a new dedicated division: Iqvia Biotech.

According to the company, the new division will design clinical and commercial solutions specifically for early-stage life sciences companies. Supported by more than 1,000 employees, the solutions suite provides simplified operating procedures, specialized teams, and services across drug development and commercialization.

“We designed this comprehensive solutions suite to address what our biotech customers were asking for — transparent and fit-for-purpose clinical processes with dedicated, therapeutically-aligned partners coupled with our unique set of enterprise capabilities,”​ said Iqvia CEO and Chairman Ari Bousbib in a press release.

Main therapy areas of focus for the new division include oncology, central nervous system, dermatology, cardiovascular, and immunology.

Iqvia also recently launched the next generation of its site portal technology to support sharing cross-trial training materials and safety notifications. Two of the top five pharmaceutical companies were involved in the design and testing, and are now using the upgraded platform, according to Iqvia.

Dedicated biotech divisions

The launch of Iqvia Biotech follows the unveiling of Parexel Biotech​ in early January – and a record-breaking 2018 in terms of biotech funding.

However, it is unlikely that this same pace will continue, though some of this is “just a healthy normalization,”Evercore ISI senior managing director and partner, equity research, Ross Muken previously told us​.

David Windley, CFA, CPA, equity analyst, Jefferies LLC, said, “Biotech funding in 2019 is probably going to be flat or maybe down a little bit versus 2018,” ​ though it is doubtful it will have the same negative effect seen in late 2015. Still, it could complicate hiring plans at CROs, but it is unlikely it will have any significant impact on the core business.

Related news

Show more

Related products

show more

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us

Products

View more

Webinars